KR102710491B1 - 안과용 조성물 - Google Patents

안과용 조성물 Download PDF

Info

Publication number
KR102710491B1
KR102710491B1 KR1020217029081A KR20217029081A KR102710491B1 KR 102710491 B1 KR102710491 B1 KR 102710491B1 KR 1020217029081 A KR1020217029081 A KR 1020217029081A KR 20217029081 A KR20217029081 A KR 20217029081A KR 102710491 B1 KR102710491 B1 KR 102710491B1
Authority
KR
South Korea
Prior art keywords
composition
ophthalmic
less
months
atropine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217029081A
Other languages
English (en)
Korean (ko)
Other versions
KR20210116688A (ko
Inventor
그레고리 아이. 오스트로우
케니스 제이. 위더
데이비드 에스. 베이커
Original Assignee
사이드넥시스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102710491(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사이드넥시스, 인크. filed Critical 사이드넥시스, 인크.
Priority to KR1020247031630A priority Critical patent/KR20240144477A/ko
Publication of KR20210116688A publication Critical patent/KR20210116688A/ko
Application granted granted Critical
Publication of KR102710491B1 publication Critical patent/KR102710491B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y10S514/912—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217029081A 2014-06-24 2015-06-23 안과용 조성물 Active KR102710491B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247031630A KR20240144477A (ko) 2014-06-24 2015-06-23 안과용 조성물

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201462016502P 2014-06-24 2014-06-24
US62/016,502 2014-06-24
US201462096433P 2014-12-23 2014-12-23
US62/096,433 2014-12-23
US201562151926P 2015-04-23 2015-04-23
US62/151,926 2015-04-23
US14/726,139 US9421199B2 (en) 2014-06-24 2015-05-29 Ophthalmic composition
US14/726,139 2015-05-29
KR1020197038476A KR20200001612A (ko) 2014-06-24 2015-06-23 안과용 조성물
PCT/US2015/037249 WO2015200361A1 (en) 2014-06-24 2015-06-23 Ophthalmic composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038476A Division KR20200001612A (ko) 2014-06-24 2015-06-23 안과용 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247031630A Division KR20240144477A (ko) 2014-06-24 2015-06-23 안과용 조성물

Publications (2)

Publication Number Publication Date
KR20210116688A KR20210116688A (ko) 2021-09-27
KR102710491B1 true KR102710491B1 (ko) 2024-09-25

Family

ID=54868660

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020217029081A Active KR102710491B1 (ko) 2014-06-24 2015-06-23 안과용 조성물
KR1020247031630A Pending KR20240144477A (ko) 2014-06-24 2015-06-23 안과용 조성물
KR1020197038476A Ceased KR20200001612A (ko) 2014-06-24 2015-06-23 안과용 조성물
KR1020177002056A Active KR102506109B1 (ko) 2014-06-24 2015-06-23 안과용 조성물

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020247031630A Pending KR20240144477A (ko) 2014-06-24 2015-06-23 안과용 조성물
KR1020197038476A Ceased KR20200001612A (ko) 2014-06-24 2015-06-23 안과용 조성물
KR1020177002056A Active KR102506109B1 (ko) 2014-06-24 2015-06-23 안과용 조성물

Country Status (22)

Country Link
US (12) US9421199B2 (enExample)
EP (3) EP3160471B1 (enExample)
JP (5) JP6678362B2 (enExample)
KR (4) KR102710491B1 (enExample)
CN (3) CN106572998B (enExample)
BR (1) BR112016030368B1 (enExample)
CA (1) CA2953363C (enExample)
DK (1) DK3160471T3 (enExample)
ES (1) ES2924243T3 (enExample)
FI (1) FIC20250034I1 (enExample)
HR (1) HRP20220972T1 (enExample)
HU (1) HUE059521T2 (enExample)
IL (1) IL249643B (enExample)
LT (1) LT3160471T (enExample)
PL (1) PL3160471T3 (enExample)
PT (1) PT3160471T (enExample)
RS (1) RS63486B1 (enExample)
SG (3) SG10201913976SA (enExample)
SI (1) SI3160471T1 (enExample)
SM (1) SMT202200447T1 (enExample)
TW (4) TW202510877A (enExample)
WO (1) WO2015200361A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
WO2017083167A1 (en) 2015-11-10 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
AU2017227585C1 (en) 2016-02-29 2022-05-26 Sun Pharmaceutical Industries Limited Topical cyclosporine-containing formulations and uses thereof
MY190011A (en) * 2016-04-11 2022-03-22 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
JP6590860B2 (ja) * 2016-05-25 2019-10-16 シンガポール ヘルス サービシーズ ピーティーイー リミテッド アトロピン含有水性組成物
KR20200007769A (ko) * 2017-02-21 2020-01-22 싱가포르 헬스 서비시즈 피티이 엘티디 아트로핀을 포함하는 근시의 발병을 방지 또는 지연하기 위한 조성물 및 방법
MY199985A (en) * 2017-03-23 2023-12-01 Santen Pharmaceutical Co Ltd Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
US10918754B2 (en) 2017-03-27 2021-02-16 Regeneron Pharmaceuticals, Inc. Sterilisation method
HRP20212019T1 (hr) * 2017-05-11 2022-04-01 Vyluma Inc. Atropinski farmaceutski sastavi
WO2018227190A1 (en) 2017-06-10 2018-12-13 Eyenovia, Inc. Methods and devices for handling a fluid and delivering the fluid to the eye
CA3070556A1 (en) * 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
AU2018371787A1 (en) * 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
WO2019136358A1 (en) 2018-01-05 2019-07-11 Iveena Delivery Systems, Inc. Treatment of myopic progression
CN110934869B (zh) * 2018-09-25 2023-07-04 沈阳兴齐眼药股份有限公司 一种阿托品药物组合物和药盒产品
CN114557955B (zh) * 2018-09-25 2024-06-18 沈阳兴齐眼药股份有限公司 药物组合物、其制备方法和用途
EP3920988A4 (en) * 2019-02-06 2022-11-02 Tearclear Corp. SYSTEMS AND METHODS FOR REMOVAL OF PRESERVATIVES FROM OPHTHALMIC FORMULATIONS INCLUDING COMPLEXING AGENTS
EP3701938B8 (en) 2019-03-01 2024-02-21 Medivis S.R.L. Ophthalmic formulations based on atropine
US20220152218A1 (en) * 2019-03-26 2022-05-19 Aura Biosciences, Inc. Human papillomavirus nanoparticle formulations
WO2020219707A1 (en) * 2019-04-24 2020-10-29 Allergan, Inc. Compositions and methods for treatment of ocular conditions
KR102308566B1 (ko) * 2019-05-28 2021-10-05 서울대학교병원 녹내장 안약의 약물이상반응 진단 키트
JP2022541152A (ja) * 2019-07-11 2022-09-22 ユニバーシティー オブ ユタ リサーチ ファウンデーション 多形態眼球製剤および治療法
JP7670704B2 (ja) * 2019-11-15 2025-04-30 シルク テクノロジーズ、リミテッド 絹由来タンパク質の安定した配合物
CN115038414A (zh) 2019-12-11 2022-09-09 艾诺维亚股份有限公司 用于向眼睛输送流体的系统和装置及使用方法
CA3164235A1 (en) * 2019-12-16 2021-06-24 Sydnexis, Inc. Ophthalmic compositions comprising d2o
CN111821259A (zh) * 2020-07-14 2020-10-27 艾尔健康眼药(辽宁)有限公司 一种眼用药物组合物
US20220031625A1 (en) * 2020-07-31 2022-02-03 Altaire Pharmaceuticals, Inc. Ophthalmic compositions for delivering meibum-like materials
US20220105101A1 (en) 2020-10-05 2022-04-07 Somerset Therapeutics, Llc Efficient brinzolamide and brimonidine compositions
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN116785286A (zh) * 2020-10-10 2023-09-22 远大生命科学(武汉)有限公司 戊乙奎醚在治疗或预防视力损伤性眼部疾病中的用途
KR102245533B1 (ko) * 2020-11-02 2021-04-28 주식회사 지게차코리아 운송수단용 림 및 이의 제조방법
EP4284362A4 (en) * 2021-01-28 2024-12-25 Glaukos Corporation Formulations
WO2022169788A1 (en) * 2021-02-03 2022-08-11 Ads Therapeutics Llc Topical ophthalmological compositions
CA3205883A1 (en) * 2021-02-04 2022-08-11 Gregory I. Ostrow Ophthalmic compositions for presbyopia
WO2022172089A1 (en) * 2021-02-12 2022-08-18 I Optima Ltd. Compound, method and system for ophthalmic surgery
CA3211874A1 (en) * 2021-03-16 2022-09-22 Kumaresh Soppimath Multi-dose container for ophthalmic compositions
EP4088713A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
EP4088714A1 (en) 2021-05-10 2022-11-16 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition comprising atropine
KR20240052048A (ko) * 2021-09-13 2024-04-22 오우푸시팡 파마수티칼 테크놀로지 씨오., 엘티디 아트로핀 점안액 및 이의 제조 방법
US12310474B2 (en) 2021-10-08 2025-05-27 Johnson & Johnson Vision Care, Inc. Multi-material lens package
EP4426353A2 (en) * 2021-11-05 2024-09-11 Calm Water Therapeutics LLC Methods for using bioadhesive and steric interactions of copolymers to minimize adverse effects
WO2023172240A1 (en) * 2022-03-07 2023-09-14 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
US20230277521A1 (en) * 2022-03-07 2023-09-07 Harrow Ip, Llc Extended-release pharmaceutical compositions for treating eye conditions
WO2023171989A1 (ko) * 2022-03-11 2023-09-14 주식회사 메디치바이오 안질환 예방 또는 치료용 약학 조성물
CA3251819A1 (en) * 2022-05-03 2023-11-09 Iview Therapeutics, Inc. Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of eye diseases
WO2024015959A1 (en) 2022-07-15 2024-01-18 Praful Doshi Methods of making and using contact lenses including medicaments and stabilizers of labile components such as drugs
US20240033260A1 (en) * 2022-07-26 2024-02-01 The Chinese University Of Hong Kong Low-concentration atropine for myopia prevention (lamp-2) study
WO2024091789A1 (en) * 2022-10-26 2024-05-02 Vyluma Inc. Childhood atropine for myopia progression
US20240316028A1 (en) * 2023-03-16 2024-09-26 Glaukos Corporation Ophthalmic cream formulations and their uses
TW202525288A (zh) * 2023-10-26 2025-07-01 英商庫博光學國際有限公司 液體組合物

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382124B1 (en) 1958-07-18 1994-10-04 Rohm & Haas Process for preparing macroreticular resins, copolymers and products of said process
NL284933A (enExample) 1961-10-31
DE1518819B1 (de) 1965-04-03 1969-12-04 Basf Ag Loesungsvermittler fuer pharmazeutische Zwecke
SE352811B (enExample) 1971-06-04 1973-01-15 Pharmacia Ab
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4255415A (en) * 1978-11-22 1981-03-10 Schering Corporation Polyvinyl alcohol ophthalmic gel
US4952586A (en) 1982-08-27 1990-08-28 The Regents Of The University Of California Edrophonium-atropine composition and therapeutic uses thereof
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
DE3644984A1 (de) 1986-07-01 1988-07-07 Eberhardt Schlueter Patrone oder ampulle fuer eine injektionsvorrichtung sowie selbsttaetige injektionsvorrichtung
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
US4852582A (en) 1987-09-11 1989-08-01 Pell Donald M Method and kit for measuring the effectiveness of bronchodilators
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
IL85312A (en) 1988-02-03 1991-08-16 Israel State Injectable pharmaceutical compositions having improved stability
JP2617508B2 (ja) * 1988-02-05 1997-06-04 エーザイ株式会社 安定なジフェンヒドラミン含有水溶液
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
FR2638428B1 (fr) 1988-10-28 1990-12-28 Transphyto Sa Conditionnement pour liquides a epurer
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5259998A (en) 1991-10-04 1993-11-09 Chiron Ophthalmics, Inc. Method for casting dissolvable ophthalmic shields in a mold
US5492689A (en) 1991-11-19 1996-02-20 The Center For Innovative Technology Combined virustatic antimediator (COVAM) treatment of common colds
US5716952A (en) 1992-03-18 1998-02-10 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
FR2702660B1 (fr) 1993-03-17 1995-05-24 Karl Simpson Compositions thérapeutiques stabilisées et leur procédé de préparation.
US5840770A (en) 1993-08-24 1998-11-24 Hill Medical Corporation Method of killing tumor cells
US5490938A (en) 1993-12-20 1996-02-13 Biopolymerix, Inc. Liquid dispenser for sterile solutions
DK1125577T3 (da) 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
GB2293100A (en) 1994-09-15 1996-03-20 Medeva Europ Ltd Pharmaceutical compositions with deuterium oxide
CZ285636B6 (cs) 1995-02-07 1999-10-13 Ústav Makromolekulární Chemie Av Čr Nové lékové formy pro farmaka aplikovaná v očním lékařství s prolongovanou účinností a způsob jejich výroby
WO1997016192A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
JP2000509971A (ja) 1996-04-10 2000-08-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 化学的シャペローンを用いる遺伝的欠陥の修正
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US20030157187A1 (en) 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
FR2770843B1 (fr) 1997-11-13 2000-01-14 Lavipharm Lab Association prolamines-lipides polaires vegetaux, son procede de preparation et ses applications
US6149670A (en) 1999-03-11 2000-11-21 Alsius Corporation Method and system for treating cardiac arrest using hypothermia
US5976499A (en) 1998-09-04 1999-11-02 Johns Hopkins University Macroscopic sweat test for cystic fibrosis
IN185228B (enExample) 1999-02-03 2000-12-09 Bakulesh Mafatlal Dr Khamar
EP1206283A2 (en) 1999-05-17 2002-05-22 Aesgen, Inc. Improved cellular uptake of bioactive agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
CN1323595A (zh) 2000-05-11 2001-11-28 朱卫国 用于青光眼的药物组合物
US20050251254A1 (en) 2000-06-02 2005-11-10 Brady Daniel G Method of implanting accommodating intraocular lenses
US20030195179A1 (en) 2000-08-25 2003-10-16 Shirou Sawa Aqueous suspension preparations
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
NZ529615A (en) 2001-05-25 2005-07-29 Valley Forge Pharmaceuticals Pirenzepine ophthalmic gel
CN1206988C (zh) 2002-05-10 2005-06-22 刘继东 硫酸阿托品眼用凝胶
WO2005016321A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
NZ579516A (en) 2004-01-27 2011-01-28 Osteotech Inc Stabilized bone graft
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US7659260B2 (en) 2005-01-14 2010-02-09 Eddie Francis Kadrmas Tamponade compositions and methods for retinal repair
MX2007009417A (es) 2005-02-04 2007-08-17 Univ Auburn Sistema de suministro de farmaco de contacto.
US9238003B2 (en) 2005-02-04 2016-01-19 Auburn University Extended or continuous wear silicone hydrogel contact lenses for the extended release of comfort molecules
CN1939534B (zh) 2005-09-27 2010-12-01 长春金赛药业股份有限公司 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
WO2007053747A2 (en) 2005-11-01 2007-05-10 President And Fellows Of Harvard College Modulating endoplasmic reticulum stress in the treatment of tuberous sclerosis
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
CN101049287A (zh) * 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) * 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
JP2007308398A (ja) * 2006-05-17 2007-11-29 Chang Gung Memorial Hospital 目薬、及びその製造方法
US7691099B2 (en) 2006-07-12 2010-04-06 Ntk Enterprises, Inc. Deuterated ocular solutions for LTK and other surgical eye procedures
WO2008096804A1 (ja) * 2007-02-07 2008-08-14 Teika Pharmaceutical Co., Ltd. ラタノプロスト含有点眼剤
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
CN101327216A (zh) 2007-06-22 2008-12-24 肖正连 一种硫酸阿托品眼用即型凝胶
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US7815605B2 (en) 2007-11-28 2010-10-19 Souter Steve R Emergency medication pump injection system
CN101468214A (zh) * 2007-12-27 2009-07-01 上海华捷视医疗设备有限公司 一种眼科手术用重水及其制备方法
DK2110132T3 (da) 2008-04-20 2014-04-28 D2 Bioscience Group Ltd Anvendelse af deuteriumoxid som elastasehæmmer
JP2012511395A (ja) 2008-12-11 2012-05-24 マサチューセッツ インスティテュート オブ テクノロジー コンタクトレンズ薬物送達デバイス
DE102009003942A1 (de) 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
WO2010083129A2 (en) * 2009-01-13 2010-07-22 The Regents Of The University Of California Implantable delivery vehicle for ocular delivery of muscarinic antagonists
TW201043211A (en) 2009-03-31 2010-12-16 Johnson & Johnson Vision Care Inc Punctal plugs
US20120203161A1 (en) * 2009-08-12 2012-08-09 Seros Medical, Llc Deuterated water and riboflavin solution for extending singlet oxygen lifetimes in treatment of ocular tissue and method of use
FR2950036B1 (fr) 2009-09-11 2011-12-16 Rexam Pharma La Verpilliere Dispositif de distribution de liquide
FR2952040B1 (fr) 2009-10-29 2011-12-30 Rexam Pharma La Verpilliere Dispositif de distribution de liquide sous forme de gouttes
WO2011098578A2 (en) 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US8945101B2 (en) * 2010-04-30 2015-02-03 Seros Medical, Llc Method and apparatus for treatment of ocular tissue using combine modalities
TWI424663B (zh) 2010-07-01 2014-01-21 Joy Ride Tech Co Ltd A motor with heat pipe
CN103118642B (zh) 2010-07-15 2015-09-09 艾诺维亚股份有限公司 液滴生成装置
CA2805425C (en) 2010-07-15 2019-07-23 Corinthian Ophthalmic, Inc. Ophthalmic drug delivery
JP5823766B2 (ja) * 2010-07-30 2015-11-25 大塚製薬株式会社 医薬組成物
TW201217533A (en) 2010-08-04 2012-05-01 Bayer Pharma AG Genomics of actinoplanes utahensis
WO2012111029A2 (en) * 2011-02-18 2012-08-23 M/S. Appasamy Associates Ophthalmic composition for enabling dilation of pupils
EP2680816A1 (en) 2011-03-03 2014-01-08 Allergan, Inc. Non-aqueous silicone-based ophthalmic formulations
KR102165246B1 (ko) 2011-04-05 2020-10-13 옵토솔브 리서치 앤드 디벨롭먼트 리미티드 안과 치료제
KR101967938B1 (ko) 2011-05-12 2019-04-10 포어사이트 바이오쎄라퓨틱스, 인코퍼레이티드 스테로이드 또는 비-스테로이드성 소염제를 갖는 안정한 포비돈-요오드 조성물
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
TW201302244A (zh) 2011-07-08 2013-01-16 Univ Nat Chiao Tung 載藥型隱形眼鏡及其製備方法
EP2785335B8 (en) 2011-11-29 2017-08-02 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of darier disease
US20170304152A1 (en) 2012-02-01 2017-10-26 Certa Dose, Inc. Apparatuses, methods, and systems for delivering medication using medication kits
HK1200109A1 (en) * 2012-02-27 2015-07-31 日本乐敦制药株式会社 Ophthalmic composition
US9814729B2 (en) 2012-03-14 2017-11-14 The Regents Of The University Of California Nerve agent antidotes
WO2013166385A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
RU2014149993A (ru) 2012-05-11 2016-07-10 Сипла Лимитед Фармацевтическая композиция
CA2873276A1 (en) 2012-05-14 2013-11-21 Eyenovia, Inc. Laminar flow droplet generator device and methods of use
SG11201407431RA (en) 2012-05-15 2014-12-30 Eyenovia Inc Ejector devices, methods, drivers, and circuits therefor
US20150297800A1 (en) 2012-07-03 2015-10-22 Sio2 Medical Products, Inc. SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
US9498035B2 (en) 2012-12-21 2016-11-22 Coopervision International Holding Company, Lp Silicone hydrogel contact lenses for sustained release of beneficial polymers
WO2014140105A1 (en) 2013-03-13 2014-09-18 D2 Bioscience Group Ltd. Materials and compositions for dental cements and filler materials
EP2978453B1 (en) 2013-03-29 2018-10-31 Onefocus Technology, LLC Drug delivery from contact lenses with a fluidic module
JP6208332B2 (ja) 2013-05-06 2017-10-04 カオシュン・チャン・グン・メモリアル・ホスピタル 医薬組成物及びその用途
TWI719401B (zh) 2013-05-17 2021-02-21 美商英塞特公司 作為jak抑制劑之聯吡唑衍生物
US9320709B2 (en) 2013-08-28 2016-04-26 Presbyopia Therapies Llc Storage stable compositions and methods for the treatment of refractive errors of the eye
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
DE102013218802B4 (de) 2013-09-19 2018-06-28 Aero Pump Gmbh Abgabevorrichtung für Fluide aus einem Fluidbehälter
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
US20160009705A1 (en) 2014-06-24 2016-01-14 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
CN106572941B (zh) 2014-08-13 2020-06-23 佛罗里达大学研究基金会股份有限公司 从眼药水中去除防腐剂
DE102015104646B3 (de) 2015-03-26 2016-06-30 Aero Pump Gmbh Abgabevorrichtung für ein Fluid
WO2016196367A1 (en) 2015-05-29 2016-12-08 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
JP6590860B2 (ja) 2016-05-25 2019-10-16 シンガポール ヘルス サービシーズ ピーティーイー リミテッド アトロピン含有水性組成物
CN109689027A (zh) 2016-06-29 2019-04-26 奥德纳米有限公司 甘油三酯耳用制剂及其用途
AU2017328907B2 (en) 2016-09-19 2020-04-09 Mexichem Fluor S.A. De C.V. Pharmaceutical composition
KR20200007769A (ko) 2017-02-21 2020-01-22 싱가포르 헬스 서비시즈 피티이 엘티디 아트로핀을 포함하는 근시의 발병을 방지 또는 지연하기 위한 조성물 및 방법
HRP20212019T1 (hr) 2017-05-11 2022-04-01 Vyluma Inc. Atropinski farmaceutski sastavi
CA3070556A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
AU2018371787A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
CA3164235A1 (en) 2019-12-16 2021-06-24 Sydnexis, Inc. Ophthalmic compositions comprising d2o

Also Published As

Publication number Publication date
EP4115884A1 (en) 2023-01-11
JP7505888B2 (ja) 2024-06-25
US10864208B2 (en) 2020-12-15
FIC20250034I1 (fi) 2025-11-28
IL249643B (en) 2021-10-31
US11890277B2 (en) 2024-02-06
CN110638749A (zh) 2020-01-03
KR20240144477A (ko) 2024-10-02
US20180042911A1 (en) 2018-02-15
US9421199B2 (en) 2016-08-23
DK3160471T3 (da) 2022-08-15
US20180193326A1 (en) 2018-07-12
JP2022062045A (ja) 2022-04-19
JP2020097599A (ja) 2020-06-25
TW202412797A (zh) 2024-04-01
US11382909B2 (en) 2022-07-12
EP3160471A4 (en) 2018-04-04
US20160339007A1 (en) 2016-11-24
HRP20220972T1 (hr) 2022-11-25
JP2017522292A (ja) 2017-08-10
SG10201707617VA (en) 2017-10-30
JP2025131595A (ja) 2025-09-09
US20200085813A1 (en) 2020-03-19
EP3689350A1 (en) 2020-08-05
KR102506109B1 (ko) 2023-03-03
US20230091109A1 (en) 2023-03-23
TW201613588A (en) 2016-04-16
TWI763620B (zh) 2022-05-11
US10842787B2 (en) 2020-11-24
US20230092957A1 (en) 2023-03-23
KR20170018962A (ko) 2017-02-20
SG10201913976SA (en) 2020-03-30
US10076515B2 (en) 2018-09-18
SI3160471T1 (sl) 2022-10-28
US20190091213A1 (en) 2019-03-28
US11896588B2 (en) 2024-02-13
US20150366854A1 (en) 2015-12-24
US20210059998A1 (en) 2021-03-04
EP3160471B1 (en) 2022-06-01
US11883390B2 (en) 2024-01-30
US20230093205A1 (en) 2023-03-23
CN115192520A (zh) 2022-10-18
PL3160471T3 (pl) 2022-09-26
WO2015200361A1 (en) 2015-12-30
CA2953363A1 (en) 2015-12-30
TW202237110A (zh) 2022-10-01
BR112016030368B1 (pt) 2022-11-01
SG11201610682UA (en) 2017-01-27
LT3160471T (lt) 2022-11-10
JP6678362B2 (ja) 2020-04-08
CN106572998B (zh) 2019-11-08
TWI855319B (zh) 2024-09-11
TW202510877A (zh) 2025-03-16
US11596625B2 (en) 2023-03-07
KR20200001612A (ko) 2020-01-06
US20210213008A9 (en) 2021-07-15
IL249643A0 (en) 2017-02-28
KR20210116688A (ko) 2021-09-27
EP3160471A1 (en) 2017-05-03
US10201534B2 (en) 2019-02-12
SMT202200447T1 (it) 2023-01-13
CA2953363C (en) 2024-02-27
TWI867694B (zh) 2024-12-21
US9770447B2 (en) 2017-09-26
US20240165098A1 (en) 2024-05-23
US20190298707A1 (en) 2019-10-03
JP2024050526A (ja) 2024-04-10
PT3160471T (pt) 2022-08-09
RS63486B1 (sr) 2022-09-30
ES2924243T3 (es) 2022-10-05
HUE059521T2 (hu) 2022-11-28
BR112016030368A2 (pt) 2018-07-17
CN106572998A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
US11883390B2 (en) Ophthalmic composition
US20160009705A1 (en) Ophthalmic composition
HK40083012A (en) Ophthalmic composition
HK40020212A (en) Ophthalmic composition
HK40029411A (en) Ophthalmic composition comprising atropine or atropine sulphate
HK1231756B (zh) 眼用组合物
HK1231756A1 (en) Ophthalmic composition

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PZ0301 Request for patent revocation

St.27 status event code: A-4-5-L10-L15-rvc-PZ0301